Patents Assigned to Dexcel Pharma Technologies Ltd.
  • Stable benzimidazole formulation
    Patent number: 12599565
    Abstract: An omeprazole delayed release tablet comprises a core and an enteric coating over the core. The core consists essentially of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate. The enteric coating over the core consists essentially of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, and less than 500 ppm of residual ammonium hydroxide.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: April 14, 2026
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Adel Penhasi, Avi Avramoff, Maxim Gomberg, Valerie Azoulay
  • METHODS FOR TREATMENT OF ANEMIA
    Publication number: 20260092281
    Abstract: Provided herein are nucleic acids and compositions thereof for inhibiting expression of transferrin receptor 2 (TFR2). Also described are methods for treatment of TFR2-associated diseases, such as anemia, with the disclosed nucleic acids.
    Type: Application
    Filed: September 25, 2025
    Publication date: April 2, 2026
    Applicant: Dexcel Pharma Technologies Ltd.
    Inventors: Nadav Marbach-Bar, Elena Feinstein, Noa Madar-Balakirski
  • Nucleic acids for inhibiting expression of transferrin receptor 2
    Patent number: 12454693
    Abstract: Provided herein are nucleic acids and compositions thereof for inhibiting expression of transferrin receptor 2 (TFR2). Also described are methods for treatment of TFR2-associated diseases, such as anemia, with the disclosed nucleic acids.
    Type: Grant
    Filed: September 27, 2024
    Date of Patent: October 28, 2025
    Assignee: Dexcel Pharma Technologies Ltd.
    Inventors: Nadav Marbach-Bar, Elena Feinstein, Noa Madar-Balakirski
  • Orally disintegrating compositions
    Patent number: 11986554
    Abstract: An orally disintegrating dosage form of a proton pump inhibitor, methods for its production and use thereof are provided. The dosage form includes a plurality of pellets containing a proton pump inhibitor admixed with a disintegrant to afford rapid disintegration in the oral cavity after administration.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: May 21, 2024
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventor: Sheera Moses-Heller
  • METHOD OF MANUFACTURING AN ORALLY DISINTIGRATING TABLET
    Publication number: 20220125730
    Abstract: An orally disintegrating composition having a bimodal particle size distribution, methods for its production and use thereof are provided.
    Type: Application
    Filed: January 7, 2022
    Publication date: April 28, 2022
    Applicant: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Sheera MOSES-HELLER, Lihi BLESSER
  • Compositions comprising dexamethasone
    Patent number: 11304961
    Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: April 19, 2022
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Caterina Kreyenborg, Elisabeth Meimberg, Corinna Tissen, Karl-Heinz Bannefeld, Tomer Gold
  • Alternating and semi-alternating poly(ester-anhydride) copolymers
    Patent number: 11299583
    Abstract: A copolymer characterized by alternating or semi-alternating ester and anhydride bonds, methods for its production and use thereof, particularly as a carrier for drug delivery, are described herein.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: April 12, 2022
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Abraham J. Domb, Michael Grishko, Ezra Hanuka, Ron Schlinger, Tal Hagigit
  • STABLE BENZIMIDAZOLE FORMULATION
    Publication number: 20220031622
    Abstract: An omeprazole delayed release tablet comprises a core and an enteric coating over the core. The core consists essentially of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate. The enteric coating over the core consists essentially of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, and less than 500 ppm of residual ammonium hydroxide.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 3, 2022
    Applicant: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Adel PENHASI, Avi Avramoff, Maxim Gomberg, Valerie Azoulay
  • Compositions comprising biodegradable copolymers for prolonged local release of an antibiotic
    Patent number: 11141488
    Abstract: A depot system containing at least one antibiotic and a biodegradable poly(ester-anhydride) of ricinoleic acid (RA) and sebacic acid (SA) having alternating or semi-alternating ester and anhydride bonds is provided. The system provides prolonged local release of the antibiotic at the site of injection while maintaining the systemic antibiotic levels at sub-therapeutic concentrations.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: October 12, 2021
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Abraham J. Domb, Michael Grishko, Ezra Hanuka, Ron Schlinger, Tal Hagigit
  • Methods for treating infection
    Patent number: 11096948
    Abstract: Composition and methods suitable for treating Helicobacter infection and diseases associated therewith are provided. The composition containing fusidic acid or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: August 24, 2021
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventor: Dan Oren
  • Orally disintegrating compositions
    Patent number: 11077055
    Abstract: An orally disintegrating dosage form of a proton pump inhibitor, methods for its production and use thereof are provided. The dosage form includes a plurality of pellets containing a proton pump inhibitor admixed with a disintegrant to afford rapid disintegration in the oral cavity after administration.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: August 3, 2021
    Assignee: Dexcel Pharma Technologies Ltd.
    Inventor: Sheera Moses-Heller
  • ALTERNATING AND SEMI-ALTERNATING POLY(ESTER-ANHYDRIDE) COPOLYMERS
    Publication number: 20210009751
    Abstract: A copolymer characterized by alternating or semi-alternating ester and anhydride bonds, methods for its production and use thereof, particularly as a carrier for drug delivery, are described herein.
    Type: Application
    Filed: August 5, 2020
    Publication date: January 14, 2021
    Applicant: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Abraham J. DOMB, Michael GRISHKO, Ezra HANUKA, Ron SCHLINGER, Tal HAGIGIT
  • Stable orally disintegrating pharmaceutical compositions
    Patent number: 10835488
    Abstract: Described herein are stable orally disintegrating tablets containing a proton pump inhibitor, methods for making the same, and methods for treating subjects in need thereof. In particular, the orally disintegrating tablets are composed of a plurality of coated units admixed with a disintegrant that demonstrate decreased friability and increased hardness.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: November 17, 2020
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Victor Pevzner, Sheera Moses-Heller
  • Alternating and semi-alternating poly(ester-anhydride) copolymers
    Patent number: 10774176
    Abstract: A copolymer characterized by alternating or semi-alternating ester and anhydride bonds, methods for its production and use thereof, particularly as a carrier for drug delivery, are described herein.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: September 15, 2020
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Abraham J. Domb, Michael Grishko, Ezra Hanuka, Ron Schlinger, Tal Hagigit
  • Compositions comprising proton pump inhibitors
    Patent number: 10736855
    Abstract: A composition suitable for forming a viscous suspension upon admixing with an aqueous medium, methods for its production and use thereof are provided. The composition includes a plurality of units, each unit having a core containing a proton pump inhibitor and an outer coating containing a gel-forming agent.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: August 11, 2020
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Tomer Gold, Irit Ventura
  • COMPOSITIONS COMPRISING DEXAMETHASONE
    Publication number: 20200147106
    Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: January 15, 2020
    Publication date: May 14, 2020
    Applicant: Dexcel Pharma Technologies Ltd.
    Inventors: Caterina KREYENBORG, Elisabeth MEIMBERG, Corinna TISSEN, Karl-Heinz BANNEFELD, Tomer GOLD
  • COMPOSITIONS COMPRISING BIODEGRADABLE COPOLYMERS
    Publication number: 20200101163
    Abstract: A depot system containing at least one antibiotic and a biodegradable poly(ester-anhydride) is provided.
    Type: Application
    Filed: March 29, 2017
    Publication date: April 2, 2020
    Applicant: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Abraham J. DOMB, Michael GRISHKO, Ezra HANUKA, Ron SCHLINGER, Tal HAGIGIT
  • Compositions comprising dexamethasone
    Patent number: 10537585
    Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: January 21, 2020
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Caterina Kreyenborg, Elisabeth Meimberg, Corinna Tissen, Karl-Heinz Bannefeld, Tomer Gold
  • OPHTHALMIC COMPOSITIONS
    Publication number: 20190209466
    Abstract: An ophthalmic composition useful for the treatment of bacterial eye infections is provided. The ophthalmic composition includes the suspension of particles of active anti-bacterial agent in a gelled matrix.
    Type: Application
    Filed: September 3, 2017
    Publication date: July 11, 2019
    Applicants: DEXCEL PHARMA TECHNOLOGIES LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Simon BENITA, Taher NASSAR
  • COMPOSITIONS COMPRISING DEXAMETHASONE
    Publication number: 20190183907
    Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: December 18, 2017
    Publication date: June 20, 2019
    Applicant: Dexcel Pharma Technologies Ltd.
    Inventors: Caterina KREYENBORG, Elisabeth MEIMBERG, Corinna TISSEN, Karl-Heinz BANNEFELD, Tomer GOLD